Influenza: Aktuelles und State of the Art - Österreichische ...
Influenza: Aktuelles und State of the Art - Österreichische ...
Influenza: Aktuelles und State of the Art - Österreichische ...
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
| kongress<br />
Fighting HIV<br />
New antiretroviral agents<br />
and novel regimens<br />
Improvements in antiretroviral <strong>the</strong>rapy (ART) have made <strong>the</strong> treatment <strong>of</strong> HIV infections more potent and<br />
better tolerated. While current treatment regimens still have limitations, <strong>the</strong>y are more effective, more<br />
convenient, and less toxic than those that were used in <strong>the</strong> early ART era. Joel E. Gallant, MD, MPH, Johns<br />
Hopkins University School <strong>of</strong> Medicine, Baltimore, Maryland, USA, discussed studies that have shown<br />
<strong>the</strong> effectiveness <strong>of</strong> new and potential ART <strong>the</strong>rapies, including single-tablet regimens, c<strong>of</strong>ormulations,<br />
nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens, CCR5 antagonists as initial <strong>the</strong>rapy,<br />
and new entry inhibitors.<br />
ECHO [NCT00540449] and THRIVE<br />
[NCT00543725], two randomized Phase<br />
3 trials, showed that <strong>the</strong> recently approved<br />
non-nucleoside reverse trans criptase<br />
inhibitor (NNRTI) rilpivirine (RPV) has<br />
sustained efficacy that is noninferior to<br />
efavirenze (EFV) in ART-naïve adults<br />
who are infected with HIV-1 [Cohen CJ<br />
et al, Lancet 2011; Molina JM et al, Lancet<br />
2011]. There were fewer discontinuations<br />
that were due to adverse events<br />
and fewer treatment-limiting side effects<br />
(especially neurological and dermatological)<br />
in <strong>the</strong> RPV arm but more virologic<br />
failure and resistance compared<br />
with <strong>the</strong> EFV arm,<br />
most notably in participants<br />
with baseline viral loads<br />
>100,000 copies/mL (Fig. 1).<br />
RPV has been approved<br />
both as a single agent and<br />
in a c<strong>of</strong>ormula tion with<br />
ten<strong>of</strong>ovir DF (TDF) and<br />
emtricitabine (FTC). It is<br />
taken once daily with a<br />
meal and is contraindi cated<br />
in patients who are taking<br />
proton pump inhibitors.<br />
In <strong>the</strong> MERIT study<br />
[NCT00098293], maraviroc<br />
(MVC) BID was not<br />
nonin ferior to EFV at